Harmony Biosciences Holdings Inc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
HRMY$33.55-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | Year Ended December 31, | ||||||||
| · 2024 · 2023 · · 2022 | |||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES · · · · | |||||||||
| Net income | | $145,493 | | $128,853 | | $181,468 | |||
| Adjustments to reconcile net income to net cash used in operating activities: | | | | | | | |||
| Depreciation | | 267 | | 514 | | | 419 | ||
| Intangible amortization | | 23,845 | | 23,845 | | | 22,966 | ||
| Acquired in-process research & development (IPR&D) expense | | | 43,595 | | | 2,260 | | | — |
| Stock-based and employee stock purchase compensation expense | | 42,602 | | 31,705 | | | 26,173 | ||
| Stock appreciation rights market adjustment | | 99 | | (499) | | | 732 | ||
| Debt issuance costs amortization | | 700 | | 2,274 | | | 1,663 | ||
| Deferred taxes | | | (29,298) | | | (13,419) | | | (85,943) |
| Amortization of premiums and accretion of discounts on Investment securities | | | (2,261) | | | (2,715) | | | (432) |
| Loss on debt extinguishment | | | — | | | 9,766 | | | — |
| Other non-cash expenses | | | 2,100 | | | 1,768 | | | 1,526 |
| Change in operating assets and liabilities: | | | | | | | |||
| Trade receivables | | (8,893) | | (19,400) | | | (19,897) | ||
| Inventory | | (1,835) | | (1,066) | | | 135 | ||
| Prepaid expenses and other assets | | (3,008) | | 74 | | | (7,548) | ||
| Trade payables | | (5,384) | | 8,949 | | | 2,785 | ||
| Other liabilities | | 11,799 | | 46,478 | | | 20,419 | ||
| Net cash provided by operating activities | | 219,821 | | 219,387 | | 144,466 | |||
| CASH FLOWS FROM INVESTING ACTIVITIES: | | | | | | ||||
| Purchase of investment securities | | | (105,289) | | | (127,469) | | | (110,729) |
| Proceeds from maturities and sales of investment securities | | | 98,527 | | | 118,309 | | | 9,069 |
| Purchase of property and equipment | | (1,153) | | (312) | | | (172) | ||
| Acquisition of Zynerba Pharmaceuticals, Inc., net of cash acquired | | — | | (36,967) | | | — | ||
| Acquisition of Epygenix Therapeutics, Inc., net of cash acquired | | | (33,069) | | | — | | | — |
| Payment of license fee and milestone | | (26,500) | | — | | | (40,000) | ||
| Net cash used in investing activities | | (67,484) | | (46,439) | | (141,832) | |||
| CASH FLOWS FROM FINANCING ACTIVITIES: | | | | | | ||||
| Proceeds from long-term debt | | — | | 200,000 | | | — | ||
| Debt issuance costs | | — | | (2,997) | | | — | ||
| Extinguishment of debt | | — | | (196,500) | | | — | ||
| Extinguishment of debt exit fees | | — | | (5,846) | | | — | ||
| Principal repayment of long-term debt | | | (15,000) | | | (4,750) | | | (2,000) |
| Repurchase of common stock | | | — | | | (100,000) | | | — |
| Payments of employee withholding taxes related to stock-based awards | | | (2,497) | | | (514) | | | — |
| Proceeds from exercised options | | 6,501 | | 5,055 | | | 8,841 | ||
| Net cash (used in) provided by financing activities | | (10,996) | | (105,552) | | | 6,841 | ||
| NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | | 141,341 | | 67,396 | | | 9,475 | ||
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH—Beginning of period | | 311,930 | | 244,534 | | | 235,059 | ||
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH—End of period | | $453,271 | | $311,930 | | | 244,534 | ||
| Supplemental Disclosure of Cash Flow Information: | | | | | |||||
| Cash paid during the year for interest | | $17,317 | | $20,051 | | $16,364 | |||
| Cash paid during the year for taxes | | | 79,635 | | | 48,233 | | | 12,645 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.